Export bans on critical biotech pharmaceuticals

Introduction

Export bans on critical biotechnology pharmaceuticals refer to government-imposed restrictions or prohibitions on exporting essential biological medicines, vaccines, therapeutic proteins, monoclonal antibodies, gene therapies and other biotechnology-based pharmaceutical products. Governments may introduce such restrictions during public health emergencies, shortages of essential medicines, national security concerns or disruptions in pharmaceutical supply chains.

Critical biotechnology pharmaceuticals play an important role in treating serious diseases, controlling infectious outbreaks and supporting public healthcare systems. Their availability may become particularly important during pandemics, humanitarian emergencies and national medical crises.

Export restrictions create a legal and ethical conflict between domestic public health priorities and international obligations concerning free trade, access to medicines and global health cooperation. Therefore, governments must ensure that export bans are legally justified, proportionate and consistent with applicable international agreements.

Meaning and objectives of export bans

An export ban is a government measure that prohibits or restricts the export of specified products to foreign countries.

In biotechnology pharmaceuticals, such restrictions may apply to vaccines, biological drugs, active pharmaceutical ingredients, diagnostic materials and other essential medical products.

The principal objectives include:

Ensuring sufficient domestic availability of essential medicines.

Preventing shortages during public health emergencies.

Protecting national healthcare systems.

Maintaining strategic pharmaceutical reserves.

Controlling the distribution of critical biological products.

Reducing dependence on international supply chains.

Protecting national security and public health interests.

Export restrictions may be temporary, product-specific or subject to government licensing arrangements.

Legal framework in India

1. Foreign Trade (Development and Regulation) Act, 1992

The Foreign Trade (Development and Regulation) Act, 1992, provides the principal statutory framework for regulating imports and exports in India.

Section 3 empowers the Central Government to make provisions for regulating, restricting or prohibiting imports and exports through official notifications.

Under this provision, the government may impose export restrictions on essential biotechnology pharmaceuticals when justified by public health, supply-chain or national-interest considerations.

The Directorate General of Foreign Trade (DGFT) implements relevant foreign trade policies and notifications.

2. Foreign Trade Policy

India's Foreign Trade Policy establishes the framework governing export permissions and restrictions.

Products may be classified as:

Free for export.

Restricted for export, requiring authorisation.

Prohibited for export.

Subject to specified conditions or exemptions.

The classification of pharmaceutical products may change through government notifications depending on domestic supply requirements and international circumstances.

3. Essential Commodities Act, 1955

The Essential Commodities Act, 1955, provides powers to regulate the production, supply and distribution of specified essential commodities.

Section 3 empowers the Central Government to issue orders regulating or prohibiting certain activities involving essential commodities.

Depending on the applicable notifications and product classification, pharmaceutical supplies may be subject to regulatory measures intended to prevent shortages and ensure equitable distribution.

4. Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act, 1940, regulates the import, manufacture, distribution and sale of drugs in India.

Biotechnology pharmaceuticals must comply with applicable requirements concerning manufacturing quality, licensing and safety. Export restrictions may operate alongside these regulatory obligations.

5. Constitution of India

Article 21 protects the right to life, while Article 47 directs the State to improve public health and nutrition.

These constitutional principles support government measures intended to maintain domestic access to essential medicines. However, restrictions must also comply with applicable constitutional requirements and cannot be arbitrary.

International legal framework

1. World Trade Organization rules

The General Agreement on Tariffs and Trade (GATT), 1994, establishes international rules concerning restrictions on exports.

Article XI generally prohibits quantitative restrictions on exports and imports, subject to recognised exceptions.

Article XI:2(a) permits certain temporary export restrictions intended to prevent or relieve critical shortages of foodstuffs or other products essential to the exporting country.

Article XX(b) allows measures necessary to protect human, animal or plant life or health, provided they satisfy the requirements of the provision and its introductory conditions.

These provisions are important when governments restrict exports of critical biotechnology pharmaceuticals during public health emergencies.

2. TRIPS Agreement

The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) establishes international minimum standards for intellectual property protection.

Articles 7 and 8 recognise the relationship between intellectual property protection, technological innovation and public welfare.

However, the TRIPS Agreement does not independently establish a general right to prohibit pharmaceutical exports. Export restrictions must be examined under the applicable international trade framework.

Major reasons for export bans

1. Public health emergencies

During pandemics and major disease outbreaks, governments may restrict exports of vaccines, biological medicines and essential therapeutic products to ensure sufficient domestic availability.

Such restrictions may be temporary and based on an assessment of national medical requirements.

2. Pharmaceutical shortages

Export restrictions may become necessary when domestic production cannot meet the requirements of hospitals and healthcare institutions.

Governments may prioritise domestic distribution until adequate supplies become available.

3. National security

Certain biotechnology products may have strategic importance because of their role in national disease preparedness and emergency medical response.

Governments may therefore treat their availability as an important national security concern.

4. Supply-chain disruptions

International transport problems, manufacturing interruptions and shortages of biological raw materials may encourage governments to impose temporary export controls.

Important case laws

1. India – Quantitative Restrictions on Imports (WTO, 1999)

In this dispute, the WTO Appellate Body examined India's quantitative import restrictions and their compatibility with GATT obligations.

Although the dispute concerned import restrictions rather than pharmaceutical export bans, it demonstrates that trade restrictions must comply with applicable WTO rules and cannot be justified merely through general policy considerations.

2. European Communities – Measures Affecting Asbestos and Asbestos-Containing Products (WTO, 2001)

The WTO Appellate Body examined public health measures involving asbestos products and recognised the importance of protecting human health within the international trade framework.

The dispute provides useful principles for understanding how health protection may justify trade-related regulatory measures, although it did not concern pharmaceutical export restrictions.

3. Thailand – Restrictions on Importation of and Internal Taxes on Cigarettes (GATT, 1990)

The GATT panel examined health-related trade restrictions and the application of public health exceptions.

The dispute is relevant by analogy because it demonstrates that public health objectives may justify certain trade measures, provided the applicable legal requirements are satisfied.

4. Vellore Citizens' Welfare Forum v. Union of India (1996)

The Supreme Court recognised the precautionary principle and polluter-pays principle as important elements of Indian environmental law.

Although the case concerned environmental protection rather than pharmaceutical exports, its reasoning supports preventive government action where serious risks to public health exist.

5. Novartis AG v. Union of India (2013)

The Supreme Court examined pharmaceutical patentability under Section 3(d) of the Patents Act, 1970, and considered the relationship between pharmaceutical innovation and public access to medicines.

The judgment is relevant to the broader debate concerning affordability, pharmaceutical innovation and access to essential treatments, although it did not directly concern export bans.

These decisions provide general principles concerning international trade restrictions, public health protection and pharmaceutical access. They do not establish a specific judicial rule authorising all export bans on biotechnology pharmaceuticals.

Challenges and legal concerns

Export bans may protect domestic patients, but excessive restrictions can create shortages in importing countries and interrupt international healthcare programmes.

Major challenges include:

Conflict between domestic medical requirements and international trade obligations.

Shortages of medicines in importing countries.

Disruption of international vaccine distribution.

Uncertainty for pharmaceutical manufacturers.

Difficulty identifying the appropriate duration of restrictions.

Risk of retaliatory trade measures.

Unequal access to essential biological medicines.

Another important concern is that prolonged restrictions may discourage international pharmaceutical investment and reduce confidence in global supply chains.

Safeguards for lawful export restrictions

Governments should adopt transparent and evidence-based policies when restricting exports of critical biotechnology pharmaceuticals.

Important safeguards include:

Establishing clear criteria for identifying critical medicines.

Conducting regular assessments of domestic pharmaceutical requirements.

Limiting restrictions to necessary products.

Providing clear reasons for export prohibitions.

Reviewing restrictions periodically.

Creating exemptions for humanitarian and emergency supplies where appropriate.

Consulting relevant international organisations and trading partners.

Ensuring compliance with WTO obligations.

Governments should also encourage domestic manufacturing capacity and international cooperation to reduce dependence on emergency export restrictions.

Conclusion

Export bans on critical biotechnology pharmaceuticals represent an important intersection of public health law, pharmaceutical regulation and international trade law. India's Foreign Trade (Development and Regulation) Act, 1992, Essential Commodities Act, 1955, and Drugs and Cosmetics Act, 1940, provide relevant domestic regulatory foundations. Internationally, GATT Articles XI and XX establish important rules governing export restrictions and public health measures. Judicial and WTO decisions demonstrate that health protection is a legitimate governmental objective, but trade restrictions must satisfy applicable legal requirements. A balanced framework should protect domestic medicine availability while maintaining international cooperation, fair trade practices and equitable access to essential biotechnology pharmaceuticals.